勃林格殷格翰能倍乐购买途径

Respimat (generic name: tiotropium bromide/olodaterol, Spiolto® Respimat®) is a drug developed by Boehringer Ingelheim. Respimat helps adult patients with chronic obstructive pulmonary disease (COPD) breathe easier. COPD is a long-term lung disease that causes shortness of breath and coughing. Respimat helps open the airways, making it easier for air to move in and out of the lungs. Normal use can also relieve persistent shortness of breath caused by the disease and help minimize the impact of the disease on daily life. At present, the drug has been approved for marketing in the country, and patients can purchase and use it with a hospital prescription.

On June 19, 2014, German pharmaceutical giant Boehringer Ingelheim announced that its new soft mist inhalation device, Slivar Respimat, was officially launched in China. Compared with traditional inhalation devices, Respimat achieves easy inhalation, efficient lung deposition, and is easy to operate and carry. The Respimat soft mist inhaler uses a long-acting anticholinergic drug (Silivar) as the agent. Modern microscopic technology allows the agent to be actively sprayed through the device. There is no need for the patient to inhale at the same time as the drug is administered, and the need for synchronized coordination is low. In addition, the aerosol of the new device lasts longer, extending to more than 1.2 seconds. The aerosol injection speed is slow, and the ideal particle content is as high as 70%, ensuring efficient deposition of drugs in the lungs, reaching 51.6%. In July 2018, Sihehua®® (tiotropium bromide/olodaterol inhalation spray) was officially approved by the China Food and Drug Administration for long-term maintenance treatment of patients with chronic obstructive pulmonary disease (including chronic bronchitis and emphysema). Recommended related articles: Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.